Business Context and Reporting Period
Company: Mineralys Therapeutics, Inc. (MLYS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 29, 2025
Subject: Announcement of detailed results from the Advance-HTN pivotal trial for lorundrostat in the treatment of uncontrolled and resistant hypertension.
Key Financial Metrics
This filing is a non-financial disclosure regarding clinical trial results. The document does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. As an emerging growth company, Mineralys Therapeutics, Inc. is in a clinical development stage, and financial performance data is not included in this specific report.
Material Changes and Clinical Results
The filing details the efficacy and safety of lorundrostat in a randomized, double-blind, placebo-controlled Phase 2 pivotal trial (Advance-HTN) involving patients on optimized background antihypertensive therapy.
Efficacy Results
- Primary Endpoint (Week 12):
- 50 mg dose: -7.9 mmHg placebo-adjusted change in 24-hour average systolic blood pressure (SBP) (p=0.001).
- 50 to 100 mg dose: -6.5 mmHg placebo-adjusted change in 24-hour average SBP (p=0.006).
- Key Secondary Endpoints (Week 4):
- 50 mg dose: -11.5 mmHg absolute change; -5.3 mmHg placebo-adjusted change (p<0.001).
- Target Achievement: 41% of patients on 50 mg achieved 24-hour average SBP < 125 mmHg vs. 18% on placebo (p<0.001).
- Subgroup Analysis: Significant reductions observed in patients on 2 background medications (-6.1 mmHg placebo-adjusted) and 3 background medications (-4.6 mmHg placebo-adjusted).
Safety and Tolerability
- Profile: Favorable safety profile with modest, rapidly reversible changes in potassium, sodium, and eGFR.
- Adverse Events:
- Serious Adverse Events (SAEs): 6% (50 mg), 8% (50-100 mg), and 2% (placebo).
- Treatment-related SAEs: 2% (50 mg), 1% (50-100 mg), and 0% (placebo).
- Hyperkalemia: Initial incidence was 5.3% (50 mg) and 7.4% (50-100 mg). After excluding spurious results per protocol, confirmed hyperkalemia rates were 2.1% and 3.2%, respectively.
- Cortisol: No suppression of cortisol production was observed.
Guidance, Outlook, and Risks
Management Commentary: The company highlighted the trial's focus on a high-risk population typically managed by specialists. The results demonstrate efficacy in lowering blood pressure with a manageable safety profile, particularly regarding electrolyte changes.
Risks and Contingencies: The filing notes that the information provided is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings unless expressly stated. Standard clinical development risks (e.g., regulatory approval, future trial outcomes) are implied but not explicitly detailed in this specific text.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional context on the trial design and statistical analysis.
- Confirm the company's current cash runway and capital requirements, as this filing does not contain financial statements.
- Monitor upcoming regulatory interactions with the FDA regarding the Phase 2 results and potential Phase 3 trial design.
- Review the specific criteria used to exclude "spurious" hyperkalemia results to understand the robustness of the safety data.
- Check for any subsequent filings regarding stock price impact or analyst reactions to the trial announcement.